Detalhe da pesquisa
1.
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer.
Nature
; 629(8014): 1142-1148, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38588696
2.
Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial.
Br J Cancer
; 129(4): 706-720, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37420000
3.
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
Lancet
; 395(10237): 1613-1626, 2020 05 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32580883
4.
SCOT: Tumor Sidedness and the Influence of Adjuvant Chemotherapy Duration on Disease Free Survival (DFS).
Clin Colorectal Cancer
; 22(2): 231-237, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36967267
5.
Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer.
Breast
; 66: 69-76, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36194950
6.
Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial.
Radiother Oncol
; 142: 52-61, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31785830
7.
Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial.
Radiother Oncol
; 120(1): 114-8, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27046390